InvestorsHub Logo
Followers 50
Posts 5075
Boards Moderated 0
Alias Born 03/23/2014

Re: ou71764 post# 11709

Thursday, 05/29/2014 11:27:19 AM

Thursday, May 29, 2014 11:27:19 AM

Post# of 732210
I think it is smart that LP is only presenting well thought out material and information, and not responding to live questions. For one, there is too much risk for a slip of the tongue regarding any questions about the blinded Phase III trail. Actually .... per FDA guidelines, even facial expressions can be considered to endanger a blinded trial ... so if she were to be on camera such as at the March presentation, just a nod or a wink could endanger the multi-million dollar trial. Not worth it. Best to keep on doing what they are doing: only provide answers to pre-screened questions. Do not inadvertently give additional info to the naysayers, AF etc.
That said, I do feel they could easily and without risk give investors some more insight on what is going on in Germany. Such as: 1 patient treated? Yes/No? When? Several? Self-paid? How much? Any progress yet on reimbursement negotiations? Yes/No/ Getting close?
LP did indicate a possible timeframe for Direct Phase I trial to be completely "enrolled" (ie including product made) = perhaps end of June. Similarly she could make some prediction about when Phase I might be completed & when Phase II might start (and how long Phase II might take). It could be something like: completion of Phase II currently expected to occur in 2H2015.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News